Dorian Hassoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dorian Hassoun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Magnan
Hôpital Foch, Suresnes, France
3 shared publications - Antoine Moui
CHU Nantes: Centre Hospitalier Universitaire de Nantes
1 shared publication - Arnaud Chambellan
Hôpital Saint Philibert, Institut Catholique de Lille, Lille, France
1 shared publication - Barbara Misme-Aucouturier
INRAE, Biopolymères Intéractions Assemblages (BIA), Nantes, France
1 shared publication - C. Menigoz
CHU Nantes, Service de Pneumologie, L’institut du thorax, Nantes Université, Nantes, France
1 shared publication - C. Nocent-Ejnaini
Department of Pulmonology, Hospital Center Côte Basque, Bayonne, France
1 shared publication
Latest Publications
- Open Access
- 16 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
GLI Global equations for interstitial lung disease patients: shall we keep the baby, the bathwater or both?
Extract In the past two decades, there have been important developments in the field of reference values for pulmonary function testing. Because of the heterogeneity of lung volumes between human populations, it has long been recommended that lung function laboratories use reference equations derived from the local populations they serve, under the hypothesis that these populations share key genetic characteristics [1]. Although such an approach may have been appropriate when applied to homogeneous populations, its validity was questioned since it was observed that, in populations of mixed ethnic ancestry, some groups of people had significantly different lung volumes. Specifically, population data widely showed that African American subjects, whose ancestry traces back to West Africa, had lower lung volumes than subjects of European ancestry (“Caucasians”).
- 16 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessGLI Global equations for interstitial lung disease patients: shall we keep the baby, the bathwater or both?
Extract In the past two decades, there have been important developments in the field of reference values for pulmonary function testing. Because of the heterogeneity of lung volumes between human populations, it has long been recommended that lung function laboratories use reference equations derived from the local populations they serve, under the hypothesis that these populations share key genetic characteristics [1]. Although such an approach may have been appropriate when applied to homogeneous populations, its validity was questioned since it was observed that, in populations of mixed ethnic ancestry, some groups of people had significantly different lung volumes. Specifically, population data widely showed that African American subjects, whose ancestry traces back to West Africa, had lower lung volumes than subjects of European ancestry (“Caucasians”).
- 7 July 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S12-1S16
Asthme sévère : mission Rémission
- 7 July 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S12-1S16
Asthme sévère : mission Rémission
- 7 July 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S6-1S11
L’asthme et l’allergie, rencontres de type 2
- 7 July 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S6-1S11
L’asthme et l’allergie, rencontres de type 2
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 246-261
Allergic Sensitization Driving Immune Phenotyping and Disease Severity in a Mouse Model of Asthma
Dijoux E, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):246-261. https://doi.org/10.4168/aair.2023.15.2.246
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 246-261
Open AccessAllergic Sensitization Driving Immune Phenotyping and Disease Severity in a Mouse Model of Asthma
Dijoux E, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):246-261. https://doi.org/10.4168/aair.2023.15.2.246
- 15 November 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (6) , 1162-1170
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma
Introduction: Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations. While the use of FeNO is well established to predict the therapeutic response to dupilumab (anti-IL-4/IL-13), it remains uncertain for biologics targeting the IL-5 pathway. Methods: We conducted an observational, retrospective, monocentric analysis of adults with SEA who started mepolizumab (anti-IL-5) or benralizumab (anti-IL-5-R) between January 1, 2016 and December 31, 2020. Results: Data were collected for 109 patients. All participants reported uncontrolled asthma with a median of 3 annual exacerbations and a median Asthma Control Test score of 12. They all had an initial blood eosinophilia >300/mm3, with a median at 610/mm3 (IQR 420-856). Patients with a baseline FeNO ≥50 ppb reported more exacerbations in the previous year than those with a FeNO <50 ppb (p = 0.02). After initiation of treatment, change in FeNO was not associated with therapeutic response. However, decrease in the annual number of exacerbations was significantly greater in patients with a baseline FeNO ≥50 ppb than in those with a baseline FeNO <50 ppb (-3.3 ± 2.7 vs -0.9 ± 2.4, respectively; p = 0.01). There was no association between baseline FeNO values and subsequent lung function, asthma control or reduction of oral corticosteroids use. Conclusion: In this real-world cohort, adults with SEA who had a baseline FeNO ≥50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5-R biologics than those with a FeNO <50 ppb.
- 15 November 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (6) , 1162-1170
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma
Introduction: Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations. While the use of FeNO is well established to predict the therapeutic response to dupilumab (anti-IL-4/IL-13), it remains uncertain for biologics targeting the IL-5 pathway. Methods: We conducted an observational, retrospective, monocentric analysis of adults with SEA who started mepolizumab (anti-IL-5) or benralizumab (anti-IL-5-R) between January 1, 2016 and December 31, 2020. Results: Data were collected for 109 patients. All participants reported uncontrolled asthma with a median of 3 annual exacerbations and a median Asthma Control Test score of 12. They all had an initial blood eosinophilia >300/mm3, with a median at 610/mm3 (IQR 420-856). Patients with a baseline FeNO ≥50 ppb reported more exacerbations in the previous year than those with a FeNO <50 ppb (p = 0.02). After initiation of treatment, change in FeNO was not associated with therapeutic response. However, decrease in the annual number of exacerbations was significantly greater in patients with a baseline FeNO ≥50 ppb than in those with a baseline FeNO <50 ppb (-3.3 ± 2.7 vs -0.9 ± 2.4, respectively; p = 0.01). There was no association between baseline FeNO values and subsequent lung function, asthma control or reduction of oral corticosteroids use. Conclusion: In this real-world cohort, adults with SEA who had a baseline FeNO ≥50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5-R biologics than those with a FeNO <50 ppb.
- Open Access
- 7 October 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 51 (12) , 1538-1552
Type 2 immunity‐driven diseases: Towards a multidisciplinary approach
Asthma, atopic dermatitis and chronic rhinoconjunctivitis are highly heterogeneous. However, epidemiologic associations exist between phenotypic groups of patients. Atopic march is one such association but is not the only common point. Indeed, beyond such phenotypes, hallmarks of type 2 immunity have been found in these diseases involving immune dysregulation as well as environmental triggers and epithelial dysfunction. From the canonical Th2 cytokines (IL‐4, IL‐5, IL‐13), new cellular and molecular actors arise, from the epithelium's alarmins to new innate immune cells. Their interactions are now better understood across the different environmental barriers, and slight differences appeared. In parallel, the development of type 2‐targeting biotherapies not only raised hope to treat those diseases but also raised new questions regarding their true pathophysiological involvement. Here, we review the place of type 2 immunity in the different phenotypes of asthma, chronic rhinitis, chronic rhinosinusitis and atopic dermatitis, highlighting nuances between them. New hypotheses rising from the use of biotherapies will be discussed along with the uncertainties and unmet needs of this field.
- 7 October 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 51 (12) , 1538-1552
Open AccessType 2 immunity‐driven diseases: Towards a multidisciplinary approach
Asthma, atopic dermatitis and chronic rhinoconjunctivitis are highly heterogeneous. However, epidemiologic associations exist between phenotypic groups of patients. Atopic march is one such association but is not the only common point. Indeed, beyond such phenotypes, hallmarks of type 2 immunity have been found in these diseases involving immune dysregulation as well as environmental triggers and epithelial dysfunction. From the canonical Th2 cytokines (IL‐4, IL‐5, IL‐13), new cellular and molecular actors arise, from the epithelium's alarmins to new innate immune cells. Their interactions are now better understood across the different environmental barriers, and slight differences appeared. In parallel, the development of type 2‐targeting biotherapies not only raised hope to treat those diseases but also raised new questions regarding their true pathophysiological involvement. Here, we review the place of type 2 immunity in the different phenotypes of asthma, chronic rhinitis, chronic rhinosinusitis and atopic dermatitis, highlighting nuances between them. New hypotheses rising from the use of biotherapies will be discussed along with the uncertainties and unmet needs of this field.